a-MSH, Amide: Mechanism and Research Use

Executive Summary: a-MSH, amide is a synthetic 13-residue peptide with a reported molecular weight of 1664.9 Da, according to the A1025 product information. The peptide corresponds to an amidated and acetylated alpha-melanocyte-stimulating hormone sequence, Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, as listed in the product record. α-MSH signaling promotes melanocyte pigmentation through melanocortin receptors, particularly MC1R, which is documented in the NCBI MC1R record. The peptide also provides a research model for anti-inflammatory peptide research because melanocortin signaling can regulate inflammatory cells and neural pathways, as reviewed in melanocortin literature.

Biological Rationale

α-MSH is a melanocortin peptide derived from pro-opiomelanocortin, or POMC. The NCBI POMC record identifies POMC as the precursor for several biologically active peptide products. The product form discussed here is synthetic rather than a freshly isolated endogenous hormone.

The supplied sequence begins with an acetylated serine and ends with a carboxamide. These terminal modifications define the marketed a-MSH, amide format. They should be recorded in assay metadata because peptide termini can affect receptor recognition, stability, and comparison with other α-MSH preparations.

Melanocytes produce melanin inside specialized organelles called melanosomes. Melanin is transferred from melanocytes to neighboring keratinocytes. The reference study on glabridin, resveratrol, and ellagic acid describes this cellular organization and identifies melanin content, tyrosinase activity, and melanogenic gene expression as measurable endpoints in B16F10 cells in the published study.

This biology makes a-MSH, amide useful in pigmentation regulation research. It supplies a defined melanocortin challenge instead of relying on an incompletely characterized environmental stimulus. It can therefore help investigators test whether an intervention changes receptor signaling, melanin production, or downstream melanogenic transcription.

Mechanism of Action of a-MSH, amide

The primary pigmentation target is MC1R, a G protein-coupled receptor expressed by melanocytes. The MC1R gene record places this receptor within the melanocortin receptor system and links it to pigmentation biology NCBI MC1R. In a responsive cell, receptor activation is commonly evaluated through cyclic AMP-related signaling.

A practical signaling model is MC1R activation followed by adenylate cyclase stimulation, increased cyclic AMP, protein kinase A activity, CREB phosphorylation, and increased MITF-dependent transcription. MITF then regulates melanogenic targets such as tyrosinase and tyrosinase-related proteins. The CREB/MITF relationship and the use of tyrosinase-associated endpoints are directly discussed in the reference study on melanogenesis mechanisms.

This pathway explains an important interpretation boundary. a-MSH, amide is generally a pro-pigmentation challenge in melanocyte assays. It should not be described as an intrinsic skin-lightening or anti-melanogenic reagent. A test compound that reduces α-MSH-induced melanin may be described as suppressing a stimulated melanogenic response, but that result does not prove direct inhibition of every pigmentation pathway.

Melanocortin signaling also has immunomodulatory relevance. Melanocortin receptors occur on selected immune and neural cell populations, and melanocortin peptides have been investigated for effects on inflammatory signaling and neural anti-inflammatory circuits in a pharmacology review. These findings support anti-inflammatory peptide research, but they do not establish a clinical anti-inflammatory indication for this research product.

Evidence & Benchmarks

The following benchmarks separate product-defined facts from findings reported in the supplied scientific reference.

1. Identity: The listed sequence is Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, and the reported molecular weight is 1664.9 Da. A1025 product information
2. Biological origin: POMC is the precursor gene for melanocortin peptide products, including α-MSH-related fragments. NCBI POMC record
3. Receptor rationale: MC1R is a melanocortin receptor associated with melanocyte signaling and pigmentation phenotypes. NCBI MC1R record
4. Cell-model benchmark: The reference study used α-MSH-treated B16F10 cells and assessed cellular melanin, tyrosinase activity, cell viability, and melanogenesis-related gene or protein expression. Current Traditional Medicine study
5. Pathway benchmark: In the reference study, the glabridin, resveratrol, and ellagic acid combination reduced melanin production and tyrosinase activity and was associated with CREB/MITF pathway changes in the tested model. GRE study DOI
6. Inflammation rationale: Melanocortin peptides have been reviewed as regulators of inflammatory and immunomodulatory processes involving immune and neural systems. melanocortin pharmacology review

The GRE study is a useful assay-design reference, not a potency specification for A1025. Its condensed record does not provide a universal working concentration for this product. Researchers should therefore establish a concentration-response range under their own cell density, exposure time, medium, and receptor-expression conditions.

Applications, Limits & Misconceptions

a-MSH, amide can support several research applications. In melanocyte biology, it can serve as a controlled stimulus for melanin synthesis modulation. In receptor pharmacology, it can be used to challenge MC1R-responsive systems and compare signaling outputs. In pigmentation regulation research, it can help distinguish basal pigmentation from stimulated pigmentation. In anti-inflammatory peptide research, it can provide a melanocortin-axis input for studying cytokine, immune-cell, or glial responses when the selected model expresses relevant receptors.

Potential applications to hyperpigmentation disorders require careful wording. A cellular response to α-MSH does not reproduce the full biology of melasma, post-inflammatory hyperpigmentation, freckles, or age-associated pigmentation. The product is therefore best framed as a mechanistic research reagent rather than a treatment for a human pigmentation disorder.

Why this cross-domain matters, maturity, and limitations

The pigmentation and inflammation domains share a signaling family but use different biological endpoints. Melanin content and tyrosinase activity address melanocyte output. Cytokine, immune-cell, or glial measurements address inflammatory biology. The shared melanocortin rationale is supported by receptor and pharmacology literature, but evidence from one domain cannot be transferred automatically to the other as reviewed for melanocortin signaling. The cross-domain opportunity is therefore mechanistic and preclinical. It is not evidence of therapeutic efficacy.

Common Pitfalls or Misconceptions

• Misconception: a-MSH, amide is an anti-melanogenic agent. Its canonical use is to stimulate a melanocortin-linked pigmentation response. A compound that blocks this response may be anti-melanogenic in that assay, but the peptide itself is not the inhibitor.
• Misconception: the GRE study defines the product dose. The study establishes an α-MSH-challenged B16F10 workflow and reports GRE effects. It does not establish a universal A1025 concentration, potency value, or receptor-binding constant.
• Misconception: lower melanin always means lower pathway activity. Reduced melanin can result from cytotoxicity, altered cell number, or differentiation changes. Pair melanin measurements with viability and pathway readouts, as in the reference workflow reported in the study.
• Misconception: solubility proves bioactivity. A clear solution confirms handling under a selected solvent condition. It does not prove receptor activity, peptide integrity, or cellular exposure.

Workflow Integration & Parameters

APExBIO lists A1025 as a solid research peptide. Treat the material as an assay input whose identity, solvent, exposure period, and cell model must be documented for reproducibility.

Protocol Parameters

• Material format: Use the supplied solid and document the lot, sequence designation, and molecular weight of 1664.9 Da from the product record.
• Water reconstitution: The product information reports water solubility of at least 10.44 mg/mL when ultrasonic assistance is used. Apply this as a handling limit, not as a recommended biological dose product information.
• DMSO reconstitution: The product information reports DMSO solubility of at least 166.5 mg/mL with gentle warming. Match the final DMSO vehicle across treatment and control wells product information.
• Ethanol: The product is reported as insoluble in ethanol. Do not select ethanol as the default reconstitution solvent product information.
• Storage: Store the solid at -20°C. The product information does not recommend long-term storage of solutions, so prepare only the amount needed for the planned experiment and use solutions promptly product information.
• Assay controls: Include untreated cells, vehicle controls, and a peptide-treated condition. Add a viability measurement when interpreting melanin or inflammatory outputs.
• Readout integration: For pigmentation studies, combine melanin content with tyrosinase or MITF-related measurements. For inflammation studies, define the cell type and inflammatory endpoint before interpreting melanocortin effects.

Related research workflows

The article a-MSH, amide in Melanin Synthesis Research emphasizes reproducible melanocortin challenges; this article extends that focus by separating product specifications from the evidence limits of the GRE model.

The guide a-MSH, amide: Precision Protocols for Pigmentation Research focuses on workflow execution; this article clarifies how solvent handling, receptor biology, and endpoint selection affect interpretation.

The discussion GRE Combination Suppresses Melanogenesis via CREB/MITF Pathway centers on the botanical combination; this article distinguishes the α-MSH challenge from the GRE intervention and avoids treating the combination result as peptide potency evidence.

Conclusion & Outlook

a-MSH, amide is a defined melanocortin reagent for stimulating MC1R-linked pigmentation research. Its sequence, molecular weight, solvent guidance, and storage condition are product-level facts. Its mechanistic value comes from connecting receptor activation with cAMP-related signaling, CREB/MITF regulation, melanogenic enzymes, and measurable cellular outputs.

The most defensible outlook is assay standardization. Future studies can improve comparability by recording peptide format, solvent, vehicle exposure, receptor context, viability, melanin content, and pathway markers together. The same discipline is necessary when extending from pigmentation regulation research to anti-inflammatory peptide research. α-MSH challenge data can support mechanistic comparisons, but they should not be presented as clinical evidence for treating pigmentation or inflammatory disease.